Cargando…

Emerging Therapeutic Biomarkers in Endometrial Cancer

Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Peixin, Kaneuchi, Masanori, Konno, Yosuke, Watari, Hidemichi, Sudo, Satoko, Sakuragi, Noriaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693108/
https://www.ncbi.nlm.nih.gov/pubmed/23819113
http://dx.doi.org/10.1155/2013/130362
_version_ 1782274706127192064
author Dong, Peixin
Kaneuchi, Masanori
Konno, Yosuke
Watari, Hidemichi
Sudo, Satoko
Sakuragi, Noriaki
author_facet Dong, Peixin
Kaneuchi, Masanori
Konno, Yosuke
Watari, Hidemichi
Sudo, Satoko
Sakuragi, Noriaki
author_sort Dong, Peixin
collection PubMed
description Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis.
format Online
Article
Text
id pubmed-3693108
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36931082013-07-01 Emerging Therapeutic Biomarkers in Endometrial Cancer Dong, Peixin Kaneuchi, Masanori Konno, Yosuke Watari, Hidemichi Sudo, Satoko Sakuragi, Noriaki Biomed Res Int Review Article Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth factor) in endometrial cancer show modest effects, there are still challenges that might remain regarding primary/acquired drug resistance and unexpected side effects on normal tissues. New studies that aim to target both genetic and epigenetic alterations (noncoding microRNA) underlying malignant properties of tumor cells and to specifically attack tumor cells using cell surface markers overexpressed in tumor tissue are emerging. More importantly, strategies that disrupt the cancer stem cell/epithelial-mesenchymal transition-dependent signals and reactivate antitumor immune responses would bring new hope for complete elimination of all cell compartments in endometrial cancer. We briefly review the current status of molecular therapies tested in clinical trials and mainly discuss the potential therapeutic candidates that are possibly used to develop more effective and specific therapies against endometrial cancer progression and metastasis. Hindawi Publishing Corporation 2013 2013-06-11 /pmc/articles/PMC3693108/ /pubmed/23819113 http://dx.doi.org/10.1155/2013/130362 Text en Copyright © 2013 Peixin Dong et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dong, Peixin
Kaneuchi, Masanori
Konno, Yosuke
Watari, Hidemichi
Sudo, Satoko
Sakuragi, Noriaki
Emerging Therapeutic Biomarkers in Endometrial Cancer
title Emerging Therapeutic Biomarkers in Endometrial Cancer
title_full Emerging Therapeutic Biomarkers in Endometrial Cancer
title_fullStr Emerging Therapeutic Biomarkers in Endometrial Cancer
title_full_unstemmed Emerging Therapeutic Biomarkers in Endometrial Cancer
title_short Emerging Therapeutic Biomarkers in Endometrial Cancer
title_sort emerging therapeutic biomarkers in endometrial cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693108/
https://www.ncbi.nlm.nih.gov/pubmed/23819113
http://dx.doi.org/10.1155/2013/130362
work_keys_str_mv AT dongpeixin emergingtherapeuticbiomarkersinendometrialcancer
AT kaneuchimasanori emergingtherapeuticbiomarkersinendometrialcancer
AT konnoyosuke emergingtherapeuticbiomarkersinendometrialcancer
AT watarihidemichi emergingtherapeuticbiomarkersinendometrialcancer
AT sudosatoko emergingtherapeuticbiomarkersinendometrialcancer
AT sakuraginoriaki emergingtherapeuticbiomarkersinendometrialcancer